3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study
Наслов
3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study
Идентификатор
/unibl/sci/idNaucniRad:25128
Тип
Пронађите сличне уносеAcademic Article
Датум
Библиографски цитат
J. Smolen, J. Choe, N. Prodanović, Y. Rho, 3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2017
Почетна страница
10
Крајња страница
10
Је дио
Пронађите сличне уносеANNALS OF THE RHEUMATIC DISEASES
Пронађите сличне уносе0003-4967
Листа аутора
Position: 43831 (119 views)